Today: 9 June 2026
Browse Category

NASDAQ:NVAX 6 November 2025 - 8 May 2026

Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax shares jumped 13% Friday after first-quarter revenue reached $139.5 million, beating estimates. Licensing and partner payments, including $30 million from Pfizer’s Matrix-M deal, offset weak COVID-19 vaccine demand. The stock traded at $10.45 with volume over 8.4 million shares. Investors await the company’s appearance at BofA’s health-care conference on May 13.
8 May 2026
···
Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat

Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat

Novavax reported first-quarter revenue of $139.5 million, beating analyst expectations but down sharply from $666.7 million a year earlier. Licensing and partner payments, including $30 million from Pfizer, offset weak COVID-19 vaccine demand. Shares rose 1.7% Thursday after a 15.6% jump Wednesday, with trading volume spiking to 16.5 million shares. Product sales fell to $42.2 million, while licensing and other revenue reached $97.3 million.
7 May 2026
··
Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax reported first-quarter revenue of $139.5 million, beating estimates as licensing and partner payments, including $30 million from Pfizer, offset weak COVID-19 vaccine sales. Shares rose 15.6% to $9.36 in afternoon trading. Product sales dropped to $42.2 million from $621.7 million a year ago. The company maintained its 2026 adjusted revenue forecast of $230 million to $270 million.
6 May 2026
··
Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax shares fell 6.4% to $8.85 at Friday’s close, underperforming the broader market. Trading volume topped 5 million shares, above the 50-day average. Investors are watching for updates on partner-driven cash, including a $30 million upfront payment expected in Q1 2026 from a license deal. Novavax delayed its profitability target to 2028 and projects 2026 adjusted revenue of $185–$205 million.
31 January 2026
····
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer shares closed up 0.8% at $26.10 Thursday, trading between $25.75 and $26.31. The gain followed news of a non-exclusive deal with Novavax for access to its Matrix‑M adjuvant, worth $30 million upfront. U.S. officials have reversed universal vaccine recommendations, shifting to “shared clinical-decision-making.” Pfizer CEO Albert Bourla blamed policy rhetoric for falling vaccination rates.
23 January 2026
···
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer shares rose 0.8% to $25.73 Wednesday after the company agreed to exit its ViiV Healthcare stake, with Shionogi paying $1.875 billion and raising its holding to 21.7%. Pfizer also secured rights to Novavax’s Matrix-M adjuvant for $30 million upfront. Both deals await regulatory clearance and do not guarantee near-term earnings growth. Investors await Pfizer’s Q4 results on Feb. 3.
21 January 2026
····
NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

Novavax (NASDAQ: NVAX) closed at $6.91 on December 5, 2025, with a market cap near $1.1 billion. Shares are down about 20% over the past year and 94% over five years. Q2 2025 saw a surprise profit on $239 million revenue, boosted by a $175 million Sanofi milestone payment, but Q3 revenue dropped to $70 million with a net loss of $202 million. The stock trades 40% below its January high.
7 December 2025
Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax (NASDAQ: NVAX) closed at $6.47 on Friday, up 4.0% but still 44% below its 52-week high. Q3 revenue beat estimates at $70 million, though losses widened and profitability is now targeted for 2028. Shah Capital is pressuring for a sale and threatening a proxy fight. The company expanded its Sanofi partnership, securing $225 million in milestones this year.
24 November 2025
·
Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax raised its FY2025 adjusted revenue outlook to $1.04–$1.06 billion after reporting Q3 revenue of $70 million, above estimates. The company posted a GAAP net loss of $202 million for the quarter, impacted by $126 million in non-cash charges tied to Maryland site consolidation and debt. Two $25 million milestone payments from Sanofi will be recognized in Q4. Cash stood at $778 million as of September 30.
6 November 2025
·····

Stock Market Today

  • Intel Corp. Stock Quote Price and Forecast
    June 8, 2026, 8:29 PM EDT. Intel Corp., a leading technology company founded in 1968, designs and sells computer products and platforms across several segments. These include Client Computing Group for personal and mobile devices, Data Center and AI for cloud and enterprise solutions, and Intel Foundry Services focusing on semiconductor manufacturing. The firm also reports results from other segments and corporate charges. Intel operates in key markets including computing, networking, data storage, and communications. Its diverse portfolio targets notebooks, desktops, servers, and communications infrastructure, positioning it as a significant player in the tech sector.

Latest articles

Chip Rally Breaks as Nasdaq Faces Tight Labor Market

Nasdaq rises after hours as chips recover

9 June 2026
Nasdaq jumped 0.86% as chip stocks rebounded, with Intel soaring 11.2% on news Google ordered over 3 million AI chips for 2028, while Apple slid 1.9% after unveiling new AI features. Investors await Wednesday’s May CPI inflation report, which could spark volatility in tech and growth stocks.
Broadcom Stock Rebounds, AI Remains an Open Question for Wall Street

Broadcom Stock Rebounds, AI Remains an Open Question for Wall Street

9 June 2026
Broadcom shares jumped 2.8% to $396.60 as chip stocks rebounded after last week’s $1 trillion sector wipeout, but investors remain cautious after Broadcom’s Q2 revenue missed expectations and the company declined to raise its 2027 AI revenue forecast, fueling concerns that rapid AI growth may not meet Wall Street’s high demands.
BitMine Stock Gains as Ether Holdings Approach 5% Target

BitMine Stock Gains as Ether Holdings Approach 5% Target

9 June 2026
BitMine Immersion Technologies shares jumped 6% after revealing ether holdings climbed to 5.54 million tokens, now 4.59% of Ethereum’s supply, with $9.6 billion in crypto, cash and stakes. The company priced a $273.8 million preferred stock offering, with proceeds possibly funding more ETH purchases and staking. BitMine projects $230 million in annualized staking revenues but warns of risks if ETH or financing falters.
Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

9 June 2026
Mingteng International shares soared 81.3% to $1.94 after the company ended its at-the-market stock sale plan, having raised about $20.6 million in gross proceeds; trading volume hit 24.2 million, dwarfing its $12 million market value, as the move outpaced gains in other U.S.-listed China auto stocks.
Go toTop